A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

Navabi, Hossein, Jasani, Bharat, Reece, Ann, Clayton, Aled ORCID: https://orcid.org/0000-0002-3087-9226, Tabi, Zsuzsanna, Donninger, C., Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869 and Adams, Malcolm 2009. A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27 (1) , pp. 107-115. 10.1016/j.vaccine.2008.10.024

Full text not available from this repository.

Abstract

Maturation of dendritic cells (DC) can be triggered in vitro by inflammatory cytokines or Toll-like receptor (TLR) ligands such as CpG or polyI:C. Corresponding, well-characterized agents which can be applied in clinical settings are sparse.We have evaluated a clinical grade, non-toxic analogue of polyI:C, poly(I:C12U) (Ampligen®), as a potential adjuvant for cancer immunotherapy, for its ability to drive maturation of human myeloid DC. Our results provide evidence that poly(I:C12U) is effective in inducing optimal phenotypic (elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40 molecules) and functional maturation of human DC in vitro, capable of promoting the production of the inflammatory (Th1-type) cytokine IL-12, with significantly lower levels of IL-10 production, compared to that induced by the parent compound polyI:C. Importantly, poly(I:C12U) has a comparable effect on the maturation and function of DCderived either fromhealthy donors or cancer patients indicating that it is able to overcome any immune suppressive factors associated with the tumour bearing state. These characteristics make poly(I:C12U) a suitable agent for use as an adjuvant in cancer directed immunotherapeutic regimes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	Q Science > QR Microbiology > QR180 Immunology R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	Dendritic cell; Maturation; Poly (I:C12U); Immunotherapy
Publisher:	Elsevier
ISSN:	0264-410X
Last Modified:	18 Mar 2023 02:06
URI:	https://orca.cardiff.ac.uk/id/eprint/25620

Citation Data

Cited 98 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item